Polymorphism of Thyroid Hormones Receptor, Angiotensin-Converting Enzyme, and High Blood Pressure in Childbearing Age Women with Hyperthyroidism

R. Agus Wibowo1,2♦, Pramudji Hastuti1,3♦, Vinayanti Susanti4♦

1Student of Doctorate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada; 2ogjakarta, Yogyakarta, Indonesia; 3National Institute Health Research and Development, Indonesia Ministry of Health; 4Department of Biochemistry Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada; 2ogjakarta, Yogyakarta, Indonesia; 3Department of Internal Medicine Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada; 2ogjakarta, Yogyakarta, Indonesia

Abstract

AIM: This study aimed to investigate the association between two polymorphisms of thyroid hormone receptor and renin-angiotensin system (THRA C/T and angiotensin-converting enzyme (ACE) I/D) genes with hypertension in childbearing age women with hyperthyroidism.

METHODS: This was a case–control study including 35 cases and 40 matched control subjects. The case group was hyperthyroid women with hypertension while the control group was hyperthyroid women with normotension. The polymorphisms were identified by a classical polymerase chain reaction.

RESULTS: The THRA C/T gene and ACE I/D polymorphisms were not associated with the hypertension while the genotype frequencies in hyperthyroid women with hypertension were as follows: CC genotype was 25.71%, CT genotype was 54.29%, and TT genotype was 20.00%. The ACE I/D genotype frequencies in hyperthyroid women with hypertension were as follows: II genotype was 23.53%, whereas in hyperthyroid women without hypertension, the I/D genotype frequencies were CC: 7.50%, CT: 72.50%, and TT: 20.00%. There were no differences in age, thyroid-stimulating hormone, FT4, systolic blood pressure (SBP), diastolic BP between subgroups in ACE I/D, and at THRA C/T polymorphisms were identified by a classical polymerase chain reaction.

CONCLUSIONS: The I allele of the ACE gene is involved in susceptibility to hypertension and polymorphism in THRA increasing concentration of FT4. There was no statistically significant difference in blood pressure between hyperthyroid women with or without hypertension.

Introduction

Thyroid hormones are important hormones for normal human growth, cell development, and metabolism in the body [1], [2]. Hyperthyroidism is the symptom of an overactive thyroid gland to produce thyroid hormones. Hyperthyroidism is characterized by weight loss, exopthalmos, nervousness, hyperagia, heat intolerance, increased pulse pressure, and tremors. Hyperthyroidism makes the thyroid gland increase production of T4 and T3 and suppresses thyroid-stimulating hormone (TSH). The most common cause of hyperthyroidism is the autoimmune disorder called Graves’ disease which is more common in women than men [1].

Hyperthyroid increases blood pressure (BP). Hypertension affects women in all phases of life, with specific characteristics relating to risk factors. Hypertension in women can occur in pregnancy, during use of contraceptives and assisted reproductive technologies, lactation, menopause, or hormone replacement therapy; hypertension often occurs in elderly women and can be related to issues of race and ethnicity [3]. Hyperthyroidism can be caused by genetic variation in the thyroid hormone receptor. Genetic predispositions of these complications of hyperthyroidism can have an obvious effect throughout the life of a patient. A few studies documented the link between THRA polymorphism rs-939348 and higher systolic BP (SBP) was a risk of hypertension [4], [5]. Another cause of hypertension is the renin-angiotensin system. It plays a major role in the homeostasis of BP. One of the enzymes of this system is the angiotensin-converting enzyme (ACE) that converts angiotensin I to angiotensin II. ACE is a peptidyl dipeptidase that releases C-terminal dipeptides from substrates [6]. ACE is an important regulator of BP and cardiovascular homeostasis. Plasma levels of ACE depend on an
insertion/deletion (I/D) polymorphism in its gene [1]. ACE is a carboxypeptidase that plays a central role in the RAS by catalyzing the conversion of angiotensin I to vasoactive angiotensin II. Polymorphism in ACE I/D will affect the secretion of this enzyme which, in turn, affects BP [7].

This research aimed to determine the impact of hyperthyroidism in women of childbearing age with THRA C/T (rs 939348) and ACE I/D genetic polymorphism and increased BP.

Materials and Methods

This was a cross-sectional observational study. The early study was conducted on 75 childbearing age women chosen from the outpatient clinic at the Clinic Health Research and Development of Magelang Central Java. Samples were diagnosed with hyperthyroidism. Participants ranged in age from 16 to 65 years and come from iodine deficiency disorder replete area. Samples were collected during the period from January 2020 to December 2020.

The whole process strictly followed the guidelines and regulations set by the Helsinki Declaration of 1975, with all amendments and revisions. The study was approved by the appropriate Institutional Ethics Committee.

Blood pressure

Systolic and diastolic BP (SBP and DBP) measurements, using the auscultation method, were performed on the left upper arm in sitting position after resting for at least 15 min using a sphygmomanometer. Hypertension was defined as mean SBP ≥140 mmHg and/or mean DBP ≥90 mmHg according to the American Heart Association recommendations.

Sample collection and handling

Fasting blood samples were collected from patients who matched the study criteria. Blood (5 mL) was withdrawn and distributed into plain tubes (3 mL) and EDTA tubes (2 mL). The blood sample in the plain tube was centrifuged after 30 min of sampling and serum was isolated and stored at −20°C and sent to the laboratory for biochemical analysis. Assays include TSH, fT4. Thyroid hormone levels were measured by enzyme-linked immunosorbent assay (ELISA) (Human.de, Germany). Samples were assayed in duplicate and the mean of the paired results was determined. EDTA tubes were stored properly at −20°C for molecular analysis.

Molecular biology techniques

Genomic DNA was extracted and purified from whole peripheral blood samples using GeneJet DNA isolation kit (Thermo Fisher Scientific). DNA stored at −80°C in aliquots until required. Amplification of the ACE gene was done by polymerase chain reaction (PCR) using PCR Master Mix (Thermo Fisher Scientific) and Veriti Thermal Cycler from Applied Biosystem.

Variation on ACE I/D

The sequence of primers used for amplification of ACE was 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' (forward) and 5'-GAT GTC GCC ATC ACA TTC GT CAG AT-3' (reverse). Amplification of the I allele is sometimes suppressed in ID genotype samples giving rise to mistyping of ID as DD in approximately 5% of cases. To avoid such mistyping, samples of the DD genotype were subjected to a second independent PCR with primers that recognize an insertion-specific sequence: 5'-TGG GAC CAC AGC GCC CAC TAC-3' (forward) and 5'-TCG CCA GCC TCT CCA TGC CCA TAA-3' (reverse). Electrophoresis was then performed on 2% agarose gels stained with SYBR Safe and the electrophoretic products were visualized using ultraviolet light transillumination. The PCR product was either 490 bp insertion (I allele) or 190 bp deletion (D allele). The second PCR with the insertion-specific primers yielded a 335 bp DNA product in the presence of the I allele and no product for homozygous DD samples (Figure 1).

Variation on THRA rs 939348

The genomic DNA was amplified using the following steps: Denaturation of double-stranded genomic DNA at 94°C for 5 min, DNA amplification using 30 cycles. Each cycle consisted of denaturation at 94°C for 30 s, annealing at 54°C for 30 s, extension at 72°C for 40 s, final elongation at 72°C for 7 min, and ending reaction at 4°C. For single-nucleotide polymorphism (SNP) rs939348, e PCR primers, foward:5` -CCT GTG TCT CCC AGC TTA GG-3`; and reverse: 5`-CCA CCA GAC TCA CAG CCT CT-3`, the PCR product was 190 bp (size of amplified fragment), the sizes of the digested fragments of the examined SNPs were C allele 190 T allele 142 and 48 bp. The restriction enzyme (MseI) digestion was done in 1 µl containing 10 units of enzyme (MseI) with 5 µl of x10 buffer and 1 µg of PCR product and incubated at 37°C for 30 min. Restriction enzyme was obtained from Thermo Fisher Scientific. Size of restricted fragments for C allele was 190 bp and T allele was 142 and 48 bp. PCR products and digested fragments were detected using electrophoresis on 2% agarose (Figure 1).
Statistical analysis

The results were presented as means ± standard deviation. The Hardy–Weinberg equilibrium was tested using $\chi^2$ to determine allelic frequency. Analysis of variance was used to assess the association between genotypes and baseline characteristics. The $\chi^2$ test was done for ascertaining the homogeneity of proportions and to determine the significance of polymorphism and risk factors.

Results

A total of 75 hyperthyroid women childbearing age were enrolled in the study. Thirty-five individuals were hyperthyroid with hypertension (case) and 40 individuals were hyperthyroid with normotension. Subjects expressed as hyperthyroidism if level TSH <0.3 μIU/mL and FT4 > 2.0 ng/dL. The Level of TSH and FT4 determined by ELISA.

Characteristically, there was no statistically significant difference between the hyperthyroid group with hypertension and hyperthyroid-normotension in the parameters of age, SBP, DBP, TSH, and FT4 ($p > 0.05$). Table 3 shows that there was no significant difference between age, TSH, SBP, and DBP between subgroups in ACE I/D. Likewise, at THRA rs-939348, there was no significant difference between age, TSH, SBP, and DBP, but there was a significant difference in the levels of FT4 concentrations (Table 3). There was no statistically significant difference between genotype TT and CC+CT with concentration of TSH ($p > 0.05$). Table 3 shows that there were differences in SBP between II genotype and ID+DD, but it was not statistically significant ($p > 0.05$). The I allele contributed to the incidence of hypertension in this study compared to the D allele.

Table 1: Demographic, biochemical, and hormonal characteristics of the studied group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control</th>
<th>Hypertension</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>40.24 ± 13.298</td>
<td>42.09 ± 12.206</td>
<td>0.071</td>
</tr>
<tr>
<td>SBP</td>
<td>122.45 ± 6.809</td>
<td>148.85 ± 14.750</td>
<td>0.070</td>
</tr>
<tr>
<td>DBP</td>
<td>72.02 ± 7.993</td>
<td>79.97 ± 10.572</td>
<td>0.157</td>
</tr>
<tr>
<td>TSH</td>
<td>0.05 ± 0.035</td>
<td>0.05 ± 0.0179</td>
<td>0.002</td>
</tr>
<tr>
<td>FT4</td>
<td>4.99 ± 2.351</td>
<td>5.01 ± 1.601</td>
<td>0.820</td>
</tr>
</tbody>
</table>

SBP: Systolic blood pressure, DBP: Diastolic blood pressure, TSH: Thyroid-stimulating hormones; FT4: Free thyroxin.

Further, comparison polymorphism in THRA rs 939348 and ACE I/D was performed on the homozygous and heterozygous of subject between subjects. No statistically significant different was found in THRA rs 939348 and ACE I/D allele and genotype frequencies with the subgroup ($p > 0.05$). The distribution of genotypes and alleles based on the Hardy–Weinberg equilibrium shows that in THRA rs 939348 is in accordance with the HWE rule ($p = 0.544$) while in ACE I/D, it is not in accordance with HWE ($p = 0.019$) (Table 2).

Table 2: Genotype distribution of polymorphisms genes (cases vs. controls)

<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>Control</th>
<th>Hypertension</th>
<th>Total</th>
<th>p value</th>
<th>HWE</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>THRA 939348</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype</td>
<td>11</td>
<td>9</td>
<td>20</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>20</td>
<td>19</td>
<td>39</td>
<td>0.233</td>
<td>0.554</td>
<td>2.800 (0.501–15.659)</td>
</tr>
<tr>
<td>CT</td>
<td>7</td>
<td>9</td>
<td>16</td>
<td>0.782</td>
<td>0.750</td>
<td>0.098–5.768</td>
</tr>
<tr>
<td>TT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allele</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>42</td>
<td>37</td>
<td>79</td>
<td>0.222</td>
<td>2.714</td>
<td>0.529–13.916</td>
</tr>
<tr>
<td>T</td>
<td>38</td>
<td>33</td>
<td>71</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE I/D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype</td>
<td>3</td>
<td>10</td>
<td>13</td>
<td>Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>29</td>
<td>18</td>
<td>47</td>
<td>0.236</td>
<td>0.019</td>
<td>4.250 (0.344–54.066)</td>
</tr>
<tr>
<td>ID</td>
<td>8</td>
<td>7</td>
<td>15</td>
<td>0.425</td>
<td>0.286</td>
<td>(0.12–6.914)</td>
</tr>
<tr>
<td>DD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allele</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>35</td>
<td>38</td>
<td>73</td>
<td>0.127</td>
<td>6.000</td>
<td>(0.478–75.344)</td>
</tr>
<tr>
<td>D</td>
<td>55</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HTRA: Thyroid hormones receptors alpha, ACE: Angiotensin-converting enzyme, OR: Odds ratio, CI: Confidence intervals, HWE: Hardy–Weinberg equilibrium.

Table 3: Association of the ACE and THRA genotype with risk factors

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SBP</th>
<th>DBP</th>
<th>TSH</th>
<th>FT4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype ACE I/D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>149.92 ± 24.74</td>
<td>78.17 ± 7.48</td>
<td>0.06 ± 0.01</td>
<td>4.30 ± 1.20</td>
</tr>
<tr>
<td>ID</td>
<td>136.63 ± 22.28</td>
<td>75.52 ± 10.38</td>
<td>0.06 ± 0.03</td>
<td>5.33 ± 1.72</td>
</tr>
<tr>
<td>DD</td>
<td>131.73 ± 13.24</td>
<td>79.02 ± 8.72</td>
<td>0.05 ± 0.01</td>
<td>5.05 ± 3.17</td>
</tr>
<tr>
<td>p value</td>
<td>0.068</td>
<td>0.397</td>
<td>0.536</td>
<td>0.279</td>
</tr>
<tr>
<td>Genotype THRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>135.66 ± 19.34</td>
<td>77.79 ± 9.27</td>
<td>0.05 ± 0.019</td>
<td>4.24 ± 1.56</td>
</tr>
<tr>
<td>CT</td>
<td>139.20 ± 22.57</td>
<td>77.88 ± 9.99</td>
<td>0.05 ± 0.025</td>
<td>5.72 ± 2.23</td>
</tr>
<tr>
<td>TT</td>
<td>137.55 ± 23.65</td>
<td>72.37 ± 8.37</td>
<td>0.07 ± 0.044</td>
<td>4.55 ± 1.48</td>
</tr>
<tr>
<td>p value</td>
<td>0.845</td>
<td>0.130</td>
<td>0.496</td>
<td>0.014</td>
</tr>
</tbody>
</table>

SBP: Systolic blood pressure, DBP: Diastolic blood pressure, TSH: Thyroid-stimulating hormones; FT4: Free thyroxin.
Discussion

Thyroid hormones act on molecular pathways in the heart and blood vessels. Disorders of the thyroid hormones can cause relevant cardiovascular disorders. Hyperthyroidism will cause several irregularities in the heart, including increased preload, high cardiac output, with increased heart rate, decreased peripheral vascular resistance, and circulating hyperdynamics [8], [9]. From the data presented, it is found that women of childbearing age have a susceptibility to suffer from hyperthyroidism which correlates with an increase in BP. Data showed that hyperthyroidism women with hypertension have SBP higher than controls although the results were not statistically significant including concentrations TSH and FT4 of both groups (Table 1).

Thyroid disease is quite common. Current estimates suggest that it affects as many as 9–15% of the adult female population and a smaller percentage of adult males. This gender-specific prevalence almost certainly results from the underlying autoimmune mechanism for the most common forms of thyroid disease, which include both Graves’ and Hashimoto’s diseases. However, with advancing age, especially beyond the eighth decade of life, the incidence of disease in males rises to be equal to that of females [10], [11].

As a result, the excess of thyroid hormone typically causes SBP to rise, and the increase can be quite dramatic in older patients with impaired arterial compliance as a result of atherosclerotic disease. Hyperthyroidism has been documented as a secondary cause of isolated systolic hypertension, which is the most common form of hypertension [10], [12]. Hypertension is a polygenic disease, and environmental and genetic as well as factors are together involved in the pathogenesis of hypertension. Some common gene variants have been associated with an increased susceptibility to develop high BP [13], [14], [15], [16], [17], [18], [19].

The ACE gene exists in chromosome 17q23. In accordance with the presence or absence of the 287 bp fragment in intron 16, there is I/D polymorphism. Some studies confirmed the presence of three genotypes: Deletion homozygous genotype DD, insertion homozygous genotype II, and heterozygous genotype ID. Importantly, in this research, ID and DD genotypes of the ACE gene were found not to be associated with hypertension in women of childbearing age with hyperthyroidism. The previous studies on ACE ID gene polymorphism in the Indian, Malaysian, and Indonesian populations showed a significant association with the DD genotype with hypertension.

In this study, genotype frequency of ACE I/D was not within the HWE rule (Table 2; p < 0.05). There are several factors that may influence alleles frequency balance in population, such as individual migration into or out of the population, presence of allele mutations, and absence of random marriage. The population of a society is highly dynamic, and the occurrence of migration and contact with other populations is inevitable. An individual in the population can have more offspring than another individual, thus contributing to the disproportion of the number of alleles in later generations. In a real population, the frequency that suits the Hardy–Weinberg model of equilibrium is rarely encountered.

In our study, which included 35 patients and 40 matched controls, we observed no significant association between ACE I/D genotypes with the study group. Our result was not consistent with other research. In humans, a positive association of the ACE D allele has been observed in some research [17]. Results in the Burkinabe and Tunisian populations also reported strong associations between the DD genotype and the risk of hypertension in their study populations. A significant association D allele with hypertension was also reported in African, Americans, Chinese, and Japanese populations [20], but not in other case–control studies of hypertension and this polymorphism. However, association studies between the D allele and the risk of hypertension did not find any evidence in the Italian population [21].

Different association was also shown in Chinese population, Italian, Greek, Japan, Indian, and Bangladesh [22], [23]. Different results were also showed in two studies from Australia and Pakistan that recorded the association of I allele with hypertension. The association of I allele with hypertension in the Pakistani population was attributed to limited number of individuals studied and to the presence of high levels of inbreeding [20].

Notably, the association between I/D polymorphism and hypertension is still controversial. Some studies have shown the association of ACE I/D polymorphism with essential hypertension and some studies failed to show the association. The controversy is due to the methodology, ethnicity, or inclusion criteria variances and further studies are needed to eliminate this controversy [20], [22], [23].

Another cause of hypertension is variation in the THRA gene. Various polymorphisms in THRA gene have been identified. Some research of this gene’s polymorphisms found a relationship with specific diseases including hypertension and coronary heart disease. This research showed significant association of this SNP rs939348 polymorphism and SBP and the risk of hypertension, but not with coronary heart disease [5]. Individuals carrying the T allele of this SNP had higher SBP than CC individuals. In a previous study, we reported on the detection of significant and consistent associations between the minor allele T of the THRA rs939348 SNP and elevated SBP in this research but the finding was not statistically significant. Consequently, this allele was also associated with higher risk of hypertension [5]. THRA rs939348 was associated with the concentration of FT4 in which
individuals with allele T have higher concentration FT4 than C allele (p < 0.05). Many polymorphisms in THRA that indicated resistance of thyroid hormones otherwise showed increase of FT4 or FT3 [24].

Polymorphism rs-939348 was not associated with variations of serum thyroid nor stimulating hormone (TSH) level in healthy subjects [25]. This is consistent with our result that showed no statistically significant difference between the case and control groups. Another research showed that this polymorphism was not associated with Alzheimer’s disease, although subjects with the TT genotype of this SNP had a tendency to have a higher risk of developing Alzheimer’s disease [25], [26]. Further, the related two polymorphic sites of the THRA gene (rs12939700 and 2390 A/G) with TSH level were investigated by Sørensen et al. in 2008 [27], and their data showed that no significant association was found.

There are very few data related to the relationship between hyperthyroidism and hypertension in Javanese ethnicity in Indonesia, especially among women of childbearing age. In theory, the occurrence of hyperthyroidism will trigger the incidence of hypertension. In addition, genetic linkages between ethnicities also affect these relationships. Different results were also possibly obtained due to limitations in this study where the data displayed were still from a preliminary study so that more samples are needed to be added to strengthen these conclusions.

Conclusions

There was a significant relationship between THRA and level concentration of FT4. This study showed no significant relationship between ACE gene polymorphism I/D and hypertension in women childbearing age with hyperthyroidism. In the analysis of the ACE genotype, it can be concluded that D allele frequency of ACE gene in women population is very low. Genotype II was a risk of hypertension in women childbearing age with hyperthyroidism.

Acknowledgments

We are grateful to Dr. Suryati Kumorowulan, Dr. Taufik Hidayat, Dr. Wayan Dani MJ, and Sri Nuryani W, clinic and laboratory staff of Magelang Health Research Development Center and all colleagues who provided technical support to the development of this paper.

Authors’ Contributions

RAW and PH: Idea/concept. Design was contributed by RAW. PH and VYS: Supervision and controlling data. Data collection/processing by RAW. Analysis/interpretation was done by RAW, PH, and VYS. Revision of the article was done by RAW, PH, and VYS. All authors have read and approved the final manuscript.

Ethics Approval and Informed Consent were required in our Study

The research protocol was approved by the Research Ethical Committee of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada. The research also conformed to the ethical guidelines of the Declaration of Helsinki, as revised in 2013. A written informed consent was obtained from all participants before enrollment in the study.

References


PMid:18844476